Effects of growth hormone (GH) replacement therapy on very low density lipoprotein apolipoprotein B100 kinetics in patients with adult GH deficiency : A stable isotope study

• Published in: The journal of clinical endocrinology and metabolism 1999, Vol.84 (1), p.307-316
• Main Authors: CHRIST, E. R, CUMMINGS, M. H, ALBANY, E, UMPLEBY, A. M, LUMB, P. J, WIERZBICKI, A. S, NAOUMOVA, R. P, BOROUJERDI, M. A, SÖNKSEN, P. H, RUSSELL-JONES, D. L
• Format: Article
• Language: English
• Subjects: Adult; Aged; Apolipoprotein B-100; Apolipoproteins B - metabolism; Biological and medical sciences; Body Composition; Double-Blind Method; Fatty Acids, Nonesterified - blood; Female; Glycated Hemoglobin A - analysis; Hormone Replacement Therapy; Hormones. Endocrine system; Human Growth Hormone - deficiency; Human Growth Hormone - therapeutic use; Humans; Insulin - blood; Lipoproteins, VLDL - metabolism; Male; Medical sciences; Mevalonic Acid - blood; Middle Aged; Pharmacology. Drug treatments
• ISSN: 0021-972X; 1945-7197
• DOI: 10.1210/jc.84.1.307

Patients with adult GH deficiency are often dyslipidemic and may have an increased risk of cardiovascular disease. The secretion and clearance of very low density lipoprotein apolipoprotein B 100 (VLDL apoB) are important determinants of plasma lipid concentrations. This study examined the effect of GH replacement therapy on VLDL apoB metabolism using a stable isotope turnover technique. VLDL apoB kinetics were determined in 14 adult patients with GH deficiency before and after 3 months GH or placebo treatment in a randomized double blind, placebo-controlled study using a primed constant [1-(13)C]leucine infusion. VLDL apoB enrichment was determined by gas chromatography-mass spectrometry. GH replacement therapy increased plasma insulin-like growth factor I concentrations 2.9 +/- 0.5-fold (P < 0.001), fasting insulin concentrations 1.8 +/- 0.6-fold (P < 0.04), and hemoglobin A1C from 5.0 +/- 0.2% to 5.3 +/- 0.2% (mean +/- SEM; P < 0.001). It decreased fat mass by 3.4 +/- 1.3 kg (P < 0.05) and increased lean body mass by 3.5 +/- 0.8 kg (P < 0.01). The total cholesterol concentration (P < 0.02), the low density lipoprotein cholesterol concentration (P < 0.02), and the VLDL cholesterol/VLDL apoB ratio (P < 0.005) decreased. GH therapy did not significantly change the VLDL apoB pool size, but increased the VLDL apoB secretion rate from 9.2 +/- 2.0 to 25.9 +/- 10.3 mg/kg x day (P < 0.01) and the MCR from 11.5 +/- 2.7 to 20.3 +/- 3.2 mL/min (P < 0.03). No significant changes were observed in the placebo group. This study suggests that GH replacement therapy improves lipid profile by increasing the removal of VLDL apoB. Although GH therapy stimulates VLDL apoB secretion, this is offset by the increase in the VLDL apoB clearance rate, which we postulate is due to its effects in up-regulating low density lipoprotein receptors and modifying VLDL composition.